Tips for Early Patient Identification for CAR T-Cell Therapy and Care Continuity with Community Providers

Advancements in the delivery of chimeric antigen receptor (CAR) T-cell therapy have led to a growing urgency to expand access across a range of care delivery settings. Since the approval of the first two CAR T-cell therapies by the Food and Drug Administration (FDA) in 2017 for acute lymphocytic leukemia and non-Hodgkin lymphoma, CAR T-cell therapy has continued to move beyond the lab with 6 currently approved therapies and more than 600 active CAR T-cell therapy trials currently underway worldwide.  Breakthroughs realized by this therapy have supported sustained remission and improved survival for some patients with hematologic malignancies, leading to significant research into the potential of CAR T-cell therapy to treat solid tumors.

Explore how ACCC is helping community cancer programs and practices acquire the education and tools needed to optimize care coordination across different care delivery settings, overcome implementation challenges, and identify patients eligible for CAR T-cell therapy early.